Costs of distributing HIV self-testing kits in Eswatini through community and workplace models.
Community
Costs and cost analysis
Eswatini
HIV
HIV self-testing
Workplace
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
29 Feb 2024
29 Feb 2024
Historique:
received:
02
05
2021
accepted:
10
10
2023
medline:
4
3
2024
pubmed:
1
3
2024
entrez:
29
2
2024
Statut:
epublish
Résumé
This study evaluates the implementation and running costs of an HIV self-testing (HIVST) distribution program in Eswatini. HIVST kits were delivered through community-based and workplace models using primary and secondary distribution. Primary clients could self-test onsite or offsite. This study presents total running economic costs of kit distribution per model between April 2019 and March 2020, and estimates average cost per HIVST kit distributed, per client self-tested, per client self-tested reactive, per client confirmed positive, and per client initiating antiretroviral therapy (ART). Distribution data and follow-up phone interviews were analysed to estimate implementation outcomes. Results were presented for each step of the care cascade using best-case and worst-case scenarios. A top-down incremental cost-analysis was conducted from the provider perspective using project expenditures. Sensitivity and scenario analyses explored effects of economic and epidemiological parameters on average costs. Nineteen thousand one hundred fifty-five HIVST kits were distributed to 13,031 individuals over a 12-month period, averaging 1.5 kits per recipient. 83% and 17% of kits were distributed via the community and workplace models, respectively. Clients reached via the workplace model were less likely to opt for onsite testing than clients in the community model (8% vs 29%). 6% of onsite workplace testers tested reactive compared to 2% of onsite community testers. Best-case scenario estimated 17,458 (91%) clients self-tested, 633 (4%) received reactive-test results, 606 (96%) linked to confirmatory testing, and 505 (83%) initiated ART. Personnel and HIVST kits represented 60% and 32% of total costs, respectively. Average costs were: per kit distributed US$17.23, per client tested US$18.91, per client with a reactive test US$521.54, per client confirmed positive US$550.83, and per client initiating ART US$708.60. Lower rates for testing, reactivity, and linkage to care in the worst-case scenario resulted in higher average costs along the treatment cascade. This study fills a significant evidence gap regarding costs of HIVST provision along the client care cascade in Eswatini. Workplace and community-based distribution of HIVST accompanied with effective linkage to care strategies can support countries to reach cascade objectives.
Sections du résumé
BACKGROUND
BACKGROUND
This study evaluates the implementation and running costs of an HIV self-testing (HIVST) distribution program in Eswatini. HIVST kits were delivered through community-based and workplace models using primary and secondary distribution. Primary clients could self-test onsite or offsite. This study presents total running economic costs of kit distribution per model between April 2019 and March 2020, and estimates average cost per HIVST kit distributed, per client self-tested, per client self-tested reactive, per client confirmed positive, and per client initiating antiretroviral therapy (ART).
METHODS
METHODS
Distribution data and follow-up phone interviews were analysed to estimate implementation outcomes. Results were presented for each step of the care cascade using best-case and worst-case scenarios. A top-down incremental cost-analysis was conducted from the provider perspective using project expenditures. Sensitivity and scenario analyses explored effects of economic and epidemiological parameters on average costs.
RESULTS
RESULTS
Nineteen thousand one hundred fifty-five HIVST kits were distributed to 13,031 individuals over a 12-month period, averaging 1.5 kits per recipient. 83% and 17% of kits were distributed via the community and workplace models, respectively. Clients reached via the workplace model were less likely to opt for onsite testing than clients in the community model (8% vs 29%). 6% of onsite workplace testers tested reactive compared to 2% of onsite community testers. Best-case scenario estimated 17,458 (91%) clients self-tested, 633 (4%) received reactive-test results, 606 (96%) linked to confirmatory testing, and 505 (83%) initiated ART. Personnel and HIVST kits represented 60% and 32% of total costs, respectively. Average costs were: per kit distributed US$17.23, per client tested US$18.91, per client with a reactive test US$521.54, per client confirmed positive US$550.83, and per client initiating ART US$708.60. Lower rates for testing, reactivity, and linkage to care in the worst-case scenario resulted in higher average costs along the treatment cascade.
CONCLUSION
CONCLUSIONS
This study fills a significant evidence gap regarding costs of HIVST provision along the client care cascade in Eswatini. Workplace and community-based distribution of HIVST accompanied with effective linkage to care strategies can support countries to reach cascade objectives.
Identifiants
pubmed: 38424538
doi: 10.1186/s12879-023-08694-y
pii: 10.1186/s12879-023-08694-y
pmc: PMC10902928
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
976Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
© 2024. The Author(s).
Références
J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25237
pubmed: 30907507
AIDS. 2020 Nov 15;34(14):2115-2123
pubmed: 32796213
Sci Rep. 2019 Sep 2;9(1):12621
pubmed: 31477764
Sex Transm Infect. 2012 Nov;88(7):498-503
pubmed: 22859498
J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25255
pubmed: 30907499
AIDS. 2018 Sep 10;32(14):2043-2049
pubmed: 29894386
J Int AIDS Soc. 2017 Feb 8;20(1):21234
pubmed: 28362073
J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25243
pubmed: 30907498
J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25245
pubmed: 30907515
PLoS Med. 2017 Nov 28;14(11):e1002458
pubmed: 29182634
PLoS One. 2017 Oct 16;12(10):e0185740
pubmed: 29036171
PLoS One. 2015 May 01;10(5):e0124476
pubmed: 25933414
PLoS Med. 2015 Sep 08;12(9):e1001873
pubmed: 26348035
PLoS Med. 2016 Nov 8;13(11):e1002166
pubmed: 27824882
BMC Med. 2016 Feb 19;14:34
pubmed: 26891969
Trop Med Int Health. 2020 Jun;25(6):723-731
pubmed: 32219945
PLoS Med. 2019 Jan 2;16(1):e1002719
pubmed: 30601823
AIDS. 2017 Jul 17;31(11):1611-1619
pubmed: 28463879
AIDS. 2008 Aug;22 Suppl 2:S67-79
pubmed: 18641472
PLoS One. 2017 Jan 26;12(1):e0170868
pubmed: 28125699
Trop Med Int Health. 2015 Jul;20(7):893-902
pubmed: 25753897